Business Wire

ÖSSUR/OTTOBOCK

25.1.2016 20:00:10 CET | Business Wire | Press release

Share
Global Prosthetics Leaders Össur and Ottobock Partner on Historic Research Trust Fund at the University of Iceland

Össur and Ottobock, two of the world’s leading prosthetics innovators, will undertake a historic joint philanthropic effort to further development in the breakthrough field of mind-controlled prosthetics, it was announced today.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160125006380/en/

Fueled by the companies’ initial combined contribution of US$1 million, the Össur and Ottobock Research Trust Fund that has been established at the University of Iceland will award international grants for scientific research and innovative projects in the field of advanced neural control of prosthetic limbs.

“Neural-controlled prosthetics is one of the greatest clinical challenges in our field, and its potential to impact lives is so significant that both companies embraced the opportunity to marshal resources and help accelerate this critical technological development,” said Thorvaldur Ingvarsson, M.D., Ph.D., Executive Vice President of Research and Development of Össur.

“Neural-controlled prosthetics could transform the lives of thousands of people with limb loss throughout the world, and we look forward to supporting the ongoing exploration of the field through the creation of this new fund,” said Dr. Hans Dietl, Chief Technology Officer of Ottobock.

The first grants from the Össur and Ottobock Research Fund at the University of Iceland will be rewarded within one year. The fund will be governed by a four-person committee, comprised of two University of Iceland representatives and one representative from each company.

“We are gratified that our University has been chosen to play a pivotal role in furthering mind-controlled prosthetics technology,” said Dr. Jón Atli Benediktsson, Rector of the University of Iceland. According to Dr. Benediktsson, details regarding the Fund’s grant application process will be announced in the near future.

About Össur

Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of Prosthetic, Osteoarthritis and Injury Solutions. A recognized “Technology Pioneer,” Össur invests significantly in research and product development—its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

About Ottobock

Around the world, the Ottobock name stands for high-quality and technologically outstanding products and services. The goal of helping to restore mobility for people - or protect what mobility they have - stands behind each and every Ottobock product. The conviction that quality of life is closely associated with a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company’s history. Since its founding in Berlin in 1919, Ottobock has pursued a vision: to improve the mobility of people with disabilities through innovative products. In doing so, the company equates quality with “Quality for life”: the quality of life enjoyed by the people who use Ottobock products every day. www.ottobock.com

Contact:

For ÖSSUR:
Laura Jackson, +1-714-745-9526
lauraminjackson@gmail.com
or
For OTTOBOCK:
Rüdiger Herzog, +49 5527 848 1859
ruediger.herzog@ottobock.de

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release

Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t

Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release

Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra

Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 16:00:00 CET | Press release

Short film follows consumers across three countries whose stories demonstrate the power of financial inclusion, innovation and resilienceKey highlights: New Experian documentary features five individuals from the United States, Brazil and the United Kingdom whose experiences illustrate the impact of financial access and opportunity. Documentary highlights examples spanning debt relief, financial education, credit empowerment and healthcare innovation. Stories showcase how Experian's products, services and social innovation can help consumers navigate challenges and pursue personal and financial goals. For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passi

Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 15:32:00 CET | Press release

The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi

Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 15:00:00 CET | Press release

FSA/HSA-Eligible Recovery Boots Deliver Five Levels of Heat and Seven Levels of Compression, Available for Pre-Order Now Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation h

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye